<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03531697</url>
  </required_header>
  <id_info>
    <org_study_id>SAN-LE-002</org_study_id>
    <nct_id>NCT03531697</nct_id>
  </id_info>
  <brief_title>Study of Loteprednol Etabonate in Adults Undergoing Bilateral Cataract Surgery</brief_title>
  <official_title>A Randomized, Single-blind, Cross-over Study of Loteprednol Etabonate in Adults Undergoing Bilateral Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sandoz</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sandoz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the bioequivalence of Loteprednol Etabonate and the reference listed
      drug (RLD)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 26, 2018</start_date>
  <completion_date type="Anticipated">February 15, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 15, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) assessed by Area Under the Curve (AUC)</measure>
    <time_frame>upon study completion, up to 1 year</time_frame>
    <description>PK for loteprednol etabonate concentrations in aqueous humor. Area under the concentration versus time curve.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) assessed by rate of drug absorption (Cmax)</measure>
    <time_frame>upon study completion, up to 1 year</time_frame>
    <description>PK for loteprednol etabonate concentrations in aqueous humor. Maximum observed mean concentration in aqueous humor over the time span specified.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Inflammation Following Ocular Surgery</condition>
  <arm_group>
    <arm_group_label>Generic Loteprednol Etabonate - RLD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Generic Loteprednol Etabonate - Period 2 (Cross-Over): Reference Listed Drug (RLD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RLD - Generic Loteprednol Etabonate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Period 1: Reference Listed Drug (RLD) - Period 2 (Cross-Over): Generic Loteprednol Etabonate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Generic Loteprednol Etabonate</intervention_name>
    <description>Drug</description>
    <arm_group_label>Generic Loteprednol Etabonate - RLD</arm_group_label>
    <arm_group_label>RLD - Generic Loteprednol Etabonate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reference Listed Drug (RLD)</intervention_name>
    <description>Drug</description>
    <arm_group_label>Generic Loteprednol Etabonate - RLD</arm_group_label>
    <arm_group_label>RLD - Generic Loteprednol Etabonate</arm_group_label>
    <other_name>Loteprednol Etabonate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must have a need for cataract surgery in both eyes and can be dosed in the
             surgical eyes.

          -  Non-pregnant, non-lactating females, or women who are post-menopausal (defined as at
             least 12 months natural, spontaneous amenorrhea), or are naturally or surgically
             sterile (hysterectomy; bilateral oophorectomy; bilateral tubal ligation with surgery
             at least 6 weeks prior to study initiation). Females of childbearing potential must
             have a confirmed absence of pregnancy according to a negative urine pregnancy test and
             must be using one of the following acceptable birth control methods: Intrauterine
             device in place for at least 90 days. Barrier method (condom or diaphragm) with
             spermicide. Stable hormonal contraceptive for at least 90 days prior to study and
             through study completion. Abstinence (if the subject becomes sexually active during
             the study she must agree to use the barrier method of birth control [condom or
             diaphragm and spermicide] for the duration of the study).

          -  Male subjects should use medically reliable contraception methods such as condom or
             vasectomy.

          -  Subjects are able to perform the activities required by the study protocol and have
             provided written informed consent.

        Exclusion Criteria:

          -  Subjects having an IOP less than 5 mmHg or greater than 24 mmHg.

          -  Known or suspected allergy or hypersensitivity to loteprednol etabonate or any
             ingredient in the formulation or container, or to other corticosteroids, including an
             increase in IOP after steroid instillation.

          -  Subjects unable to tolerate instillation of study product by the investigator or
             qualified staff.

          -  Use of other investigational drugs within 30 days prior to dosing and for the duration
             of the study.

          -  Subject has used any medication, by any route, containing loteprednol etabonate within
             7 days prior to Visit 1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandoz</last_name>
    <role>Study Director</role>
    <affiliation>Sandoz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41-61-3241111</phone>
    <email>clinicaltrial.enquiries@novartis.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Multiple Locations</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Multiple Locations</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2018</study_first_submitted>
  <study_first_submitted_qc>May 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2018</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Loteprednol Etabonate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Loteprednol Etabonate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

